Samsung Biologics and Bristol-Myers Squibb announce Biopharmaceutical Manufacturing Relationship

Seoul(Korea) July 29th, – 2013 Samsung Biologics and Bristol-Myers Squibb Company announced the companies have entered into a 10-year agreement under which Samsung Biologics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013.
For more informations, please enter the following address.

Seoul(Korea) July 29th, 2013 – Samsung Biologics and Bristol-Myers Squibb Company announced the companies have entered into a 10-year agreement under which Samsung Biologics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013.
For more informations, please enter the following address.
Share article
Related Content